Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Olaparib

FDA-approved product (capsule, oral), marketed as Lynparza.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Olaparib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Neoplasm
  • Ovarian cancer
  • Ovarian carcinoma
  • Ovarian neoplasm
  • Pancreatic carcinoma
  • Pancreatic neoplasm
  • Prostate cancer
  • Prostate carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Poly (adp-ribose) polymerase (parp) inhibitors
FDA pharmacologic class
Poly(ADP-Ribose) Polymerase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA69.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli55.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae48.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Olaparib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Olaparib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)

    NCT07475923 · start 2026-04-09

    Registered record
    Registry ID
    NCT07475923
    Conditions
    Molecular Surveillance; Breast Cancer; ctDNA; MRD; Observational Study
    Interventions
    Blood draw for the laboratory assessment; Neoadjuvant treatment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2026-04-09
    Completion
    2026-04-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMolecular Surveillance; Breast Cancer; ctDNA; MRD +1 more
    InterventionBlood draw for the laboratory assessment; Neoadjuvant treatment
    PhaseNot recorded
    Registry statusWithdrawn

  • An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors

    NCT07371663 · start 2025-12-03

    Registered record
    Registry ID
    NCT07371663
    Conditions
    Solid Cancers; NSCLC (Advanced Non-small Cell Lung Cancer); Gastric (Stomach) Cancer; Endometrial Cancer; Malignant Melanoma
    Interventions
    TCC1727 tablet 90mg; TCC1727 tablet 120mg; TCC1727 tablet 160mg; benmelstobart Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2025-12-03
    Completion
    2029-06-30
    Enrolment
    266

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Cancers; NSCLC (Advanced Non-small Cell Lung Cancer); Gastric (Stomach) Cancer; Endometrial Cancer +1 more
    InterventionTCC1727 tablet 90mg; TCC1727 tablet 120mg; TCC1727 tablet 160mg; benmelstobart Injection
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance

    NCT06995833 · start 2025-09-19

    Registered record
    Registry ID
    NCT06995833
    Conditions
    Endometrial Cancer
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-09-19
    Completion
    2029-06-29
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometrial Cancer
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)

    NCT07113964 · start 2025-08-30

    Registered record
    Registry ID
    NCT07113964
    Conditions
    Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency
    Interventions
    QL1706 + olaparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-08-30
    Completion
    2029-03-30
    Enrolment
    79

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPreviously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency
    InterventionQL1706 + olaparib
    PhasePhase 2
    Registry statusNot yet recruiting

  • FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    NCT06909825 · start 2025-02-26

    Registered record
    Registry ID
    NCT06909825
    Conditions
    Metastatic Castration-resistant Prostate Cancer
    Interventions
    FPI-2265; Olaparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2025-02-26
    Completion
    2027-05
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-resistant Prostate Cancer
    InterventionFPI-2265; Olaparib
    PhasePhase 2
    Registry statusActive not recruiting

  • Detection of Homologous Recombination Pathway Gene Mutations in Circulating Tumour DNA From BRCA-mutated Ovarian Cancer Patients Receiving First-line PARP Inhibitor Maintenance Therapy

    NCT06588322 · start 2025-01-08

    Registered record
    Registry ID
    NCT06588322
    Conditions
    Ovarian Cancer
    Interventions
    Blood samples will be taken on several times (36 mL of blood taken at each time):
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-01-08
    Completion
    2029-11
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer
    InterventionBlood samples will be taken on several times (36 mL of blood taken at each time):
    PhaseNot applicable
    Registry statusRecruiting

  • Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

    NCT05485766 · start 2024-07-16

    Registered record
    Registry ID
    NCT05485766
    Conditions
    Triple Negative Breast Neoplasms; Triple Negative Breast Cancer; Breast Neoplasms; Breast Cancer; BRCA1 Mutation; BRCA2 Mutation; BRCA Mutation; BRCA-Associated Breast Carcinoma
    Interventions
    Pembrolizumab; Paclitaxel; Carboplatin; Olaparib; Definitive Surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-07-16
    Completion
    2028-09-30
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTriple Negative Breast Neoplasms; Triple Negative Breast Cancer; Breast Neoplasms; Breast Cancer +4 more
    InterventionPembrolizumab; Paclitaxel; Carboplatin; Olaparib +1 more
    PhasePhase 2
    Registry statusRecruiting

  • Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma

    NCT06160843 · start 2024-07-01

    Registered record
    Registry ID
    NCT06160843
    Conditions
    Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-Cell Lymphoma
    Interventions
    Pembrolizumab IV infusion Q3W, with daily oral Olaparib.
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-07-01
    Completion
    2028-01
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-Cell Lymphoma
    InterventionPembrolizumab IV infusion Q3W, with daily oral Olaparib.
    PhasePhase 2
    Registry statusRecruiting

  • Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd

    NCT06298084 · start 2024-03-21

    Registered record
    Registry ID
    NCT06298084
    Conditions
    Breast Cancer Metastatic; HER2-positive Metastatic Breast Cancer; HER2 Low Breast Carcinoma; Advanced Breast Cancer
    Interventions
    Patritumab deruxtecan; Olaparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2024-03-21
    Completion
    2029-06
    Enrolment
    152

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer Metastatic; HER2-positive Metastatic Breast Cancer; HER2 Low Breast Carcinoma; Advanced Breast Cancer
    InterventionPatritumab deruxtecan; Olaparib
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma

    NCT05286827 · start 2023-12-14

    Registered record
    Registry ID
    NCT05286827
    Conditions
    Pancreatic Acinar Cell Carcinoma
    Interventions
    Olaparib; ECG; CT CAP; Tumor Biopsy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2023-12-14
    Completion
    2025-09-25
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Acinar Cell Carcinoma
    InterventionOlaparib; ECG; CT CAP; Tumor Biopsy
    PhasePhase 2
    Registry statusTerminated

  • Implantable Microdevice for TNBC - Pilot Study

    NCT05774886 · start 2023-05

    Registered record
    Registry ID
    NCT05774886
    Conditions
    Triple Negative Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III; Breast Cancer; Early Stage Triple-Negative Breast Carcinoma; Breast Neoplasms; Breast Carcinoma
    Interventions
    Implantable Microdevice (IMD)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2023-05
    Completion
    2028-09-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTriple Negative Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III; Breast Cancer +3 more
    InterventionImplantable Microdevice (IMD)
    PhasePhase 1
    Registry statusWithdrawn

  • Olaparib Maintenance Therapy in Metastatic Breast Cancer

    NCT05629429 · start 2023-02-07

    Registered record
    Registry ID
    NCT05629429
    Conditions
    Metastatic Breast Cancer
    Interventions
    Olaparib; Chemotherapy drug
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-02-07
    Completion
    2025-12-31
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionOlaparib; Chemotherapy drug
    PhasePhase 2
    Registry statusUnknown

  • Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

    NCT05498272 · start 2023-02-01

    Registered record
    Registry ID
    NCT05498272
    Conditions
    Prostate Cancer; BRCA1 Mutation; BRCA2 Mutation; Prostatic Adenocarcinoma; High-Risk Cancer
    Interventions
    Olaparib; LHRH agonist
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-02-01
    Completion
    2026-12
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; BRCA1 Mutation; BRCA2 Mutation; Prostatic Adenocarcinoma +1 more
    InterventionOlaparib; LHRH agonist
    PhasePhase 2
    Registry statusActive not recruiting

  • Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor

    NCT05536128 · start 2022-12-31

    Registered record
    Registry ID
    NCT05536128
    Conditions
    Advanced Breast Cancer
    Interventions
    Olaparib; Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-12-31
    Completion
    2025-12-31
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Breast Cancer
    InterventionOlaparib; Fulvestrant
    PhasePhase 2
    Registry statusRecruiting

  • A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer

    NCT05258747 · start 2022-04-07

    Registered record
    Registry ID
    NCT05258747
    Conditions
    Ovarian Cancer; Breast Cancer
    Interventions
    Olaparib tablets, 150 mg; Lynparza® (olaparib) tablets 150 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-04-07
    Completion
    2022-10-20
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer; Breast Cancer
    InterventionOlaparib tablets, 150 mg; Lynparza® (olaparib) tablets 150 mg
    PhasePhase 1
    Registry statusCompleted